A phase II study of tasisulam sodium (LY573636 sodium) as second-line or third-line treatment for patients with unresectable or metastatic soft tissue sarcoma

Christopher W. Ryan, Chacon Matias, Mark Agulnik, Antonio Lopez-Pousa, Charles Williams, Dinesh P. De Alwis, Christopher Kaiser, Mary Alice Miller, Sabine Ermisch, Robert Ilaria, M. L. Keohan

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Fingerprint

Dive into the research topics of 'A phase II study of tasisulam sodium (LY573636 sodium) as second-line or third-line treatment for patients with unresectable or metastatic soft tissue sarcoma'. Together they form a unique fingerprint.

Medicine & Life Sciences